{
  "input": {
    "mode": "build_chain",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_bimekizumab",
          "name": "Bimekizumab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_ixekizumab",
          "name": "Ixekizumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_tazarotene",
          "name": "Tazarotene"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 3
    },
    "constraints": {
      "require_disjoint_paths": 2,
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_bimekizumab",
          "type": "Drug",
          "label": "Bimekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tazarotene",
          "type": "Drug",
          "label": "Tazarotene",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "d_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_immune_response",
          "type": "Target",
          "label": "Immune Response",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_symptomatic_relief",
          "type": "Phenotype",
          "label": "Symptomatic Relief",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_skin_remission",
          "type": "Phenotype",
          "label": "Skin Remission",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_acitretin",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "常用治疗在免疫调节上有效"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "靶向 TNF-α 的治疗策略"
        },
        {
          "source": "drug_apremilast",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "抑制炎症通路的机制"
        },
        {
          "source": "drug_bimekizumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "IL-17靶向作用"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-17A拮抗剂"
        },
        {
          "source": "drug_cyclosporine",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "免疫抑制机制支持"
        },
        {
          "source": "drug_etanercept",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "抑制炎症反应"
        },
        {
          "source": "drug_ixekizumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "IL-17E 的抵抗并促进重建"
        },
        {
          "source": "drug_methotrexate",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "作为传统治疗药物的有效性"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "针对 IL-17A 的特异性干预"
        },
        {
          "source": "drug_tazarotene",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "调控分化的机制"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_immune_response",
          "relation": "acts_on",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "靶向 IL-12/23 的选择性"
        },
        {
          "source": "target_immune_response",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "支持的通路连接"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "d_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "与通路在病理过程中的一致性"
        },
        {
          "source": "drug_acitretin",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "已知的临床表现改善"
        },
        {
          "source": "drug_adalimumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "有效性证据强"
        },
        {
          "source": "drug_apremilast",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "机制的有效性总结"
        },
        {
          "source": "drug_bimekizumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "靶向的有效性"
        },
        {
          "source": "drug_brodalumab",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "支持的临床证据"
        },
        {
          "source": "drug_cyclosporine",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "提高患者群体的好转率"
        },
        {
          "source": "drug_etanercept",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "发挥快速生效"
        },
        {
          "source": "drug_ixekizumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "针对于根据临床效果获得改善"
        },
        {
          "source": "drug_methotrexate",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "已知的改善作用"
        },
        {
          "source": "drug_secukinumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "可期待的病理改善"
        },
        {
          "source": "drug_tazarotene",
          "target": "phenotype_symptomatic_relief",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "局部疗法已知效果"
        },
        {
          "source": "drug_ustekinumab",
          "target": "phenotype_skin_remission",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "支持慢性病例治疗的有效性"
        }
      ],
      "merge": [],
      "set_weights": []
    },
    "subconclusions": [
      {
        "id": "C1",
        "text": "多种药物通过不同的机制作用于免疫反应通路，改善皮肤症状与缓解相关病理特征",
        "confidence": "high"
      },
      {
        "id": "C2",
        "text": "策略的选择可能基于患者的特定病情以及可能的反应不同",
        "confidence": "medium"
      }
    ],
    "assumptions": [
      "所有药物在临床上显示出一定的有效性并可合理用来治疗该病"
    ],
    "uncertainties": [
      "药物对皮肤症状的具体影响程度需要进一步研究验证"
    ],
    "next_focus_for_pi": [
      "需要确认每种药物机制的细节以及最佳治疗方案的临床实践"
    ]
  }
}